Prognostic Significance of Epidermal Growth Factor Receptor (Egfr) in Head and Neck Tumours at Some Selected Hospital in Ghana (original) (raw)
Related papers
Prognostic Worth of Epidermal Growth Factor Receptor (EGFR) in Patients with Head and Neck Tumors
Journal of Cancer Epidemiology
Introduction. Head and neck tumors (HNT) are tumors that normally occur at the head and neck region of the body. Epidermal growth factor receptor (EGFR) has been found to be highly expressed in breast and other tumors; therefore, there is the need to investigate the level of EGFR expression among patients with head and neck tumors in Ghana. Method. The level of EGFR expression was determined in head and neck tumor and control head and neck tissues with quantitative real-time PCR and immunohistochemistry analysis. Results. The level of EGFR expressions was high in tumor tissues than in the control tissues. There was a significant difference of p value 0.025 among the ages >40 and ≤ 40 when the high and low level of EGFR was compared in the head and neck malignant tumor. The area under the curve for the high expression of EGFR among the malignant head and neck tumors was 0.901 with a specificity of 86.4%. Conclusion. EGFR can serve as a prognostic marker in monitoring patients with...
Head & Neck, 1991
Epidermal growth factor (EGF) stimulates the growth of several types of epithelial tissues and possesses a strong mitogenic activity that is mediated through its cell surface receptor (EGFR). The aim of this study was to characterize EGFR and measure its levels in head and neck tumors biopsies (70 patients); use of a simplified competition technique with a radiolabeled ligand allowed evaluation of functional EGFR. Five samples (4 tumors and 1 control) were used to characterize EGF binding. Graphic representation identified a single family of binding sites. Kd values revealed high affinity for EGF binding: mean Kd, 0.156 f 0.1 08 nM (0.095-0.347 nM). EGF-binding characteristics (Kd) tion was found between EGFR levels and tumor size and stage. Controls exhibited a trend toward higher EGFR levels in elevated sizes and stages. According to a cutoff EGFR value of 100 frnol/rng protein, which separated all controls from tumors, EGFR-positive tumors (>lo0 fmol/mg protein) had a greater probability of complete response to chemotherapy than EGFRnegative tumors; other tumor characteristics, such as the degree of tumoral differentiation, tumor size, or stage, were unable to operate such a discrimination in the response to chemotherapy. EGFR may thus be an interesting biological marker for head and neck cancer. HEAD & NECK 1991;13:132-139 were similar in nontumoral tissue samples (controls) and in tumor material. In 59 of 60 cases, EGFR levels were higher in the tumor than in the corresponding controls. A significant correla-Epidermal growth factor (EGF) is a growth factor polypeptide with a molecular weight of 6,000 daltons, which was described by Cohen' in the mouse submaxillary gland. EGF stimulates the growth of several types of epithelial tissues and diated through its surface receptor (EGFR)* The intracellular component of EGFR is very similar to the V-erb p oncogene product2 In human cancer, the presence of EGFR has been reported in the b r e a~t ,~*~ lung: bladder,6 brain,7 ovaries,' thyroid,' and aerodigestive tract.lO." In these localizations, EGFR has been measured directly, by ligand-binding methods, or indirectly,
Oncology letters, 2016
Approximately 90% of all head and neck tumors are squamous cell carcinomas. The overall survival of patients with head and neck squamous cell carcinoma (HNSCC) is low (≤50%). A non-invasive marker of disease progression is sorely required. The present study focused on the plasmatic levels of epidermal growth factor receptor (EGFR) in HNSCC patients (N=92) compared with healthy (N=29) and diabetic [type 2 diabetes mellitus (T2DM); N=26] controls. Enzyme-linked immunosorbent assay using antibodies against the extracellular region of EGFR (L25-S645) was performed. No significant changes were observed between diabetic and healthy controls. However, there were significantly higher EGFR plasma levels in HNSCC patients compared with both control groups (P=0.001 and 0.005, respectively). Receiver operating characteristic curve analysis identified a sensitivity of 76.09%, a specificity of 67.27% and an area under curve of 0.727 for this comparison. No significant association was observed bet...
Medical oncology (Northwood, London, England), 2017
In an era of personalized treatment, there is a great interest in identifying factors which might predict patient response to radiotherapy (RT). The role of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinoma (HNSCC) remains still controversial. We performed a retrospective analysis on the prognostic value of EGFR in HNSCC patients treated with surgery and postoperative RT through a semiquantitative immunohistochemical analysis of EGFR membrane expression. We retrospectively analyzed 65 HNSCC patients treated in our Institute from 1997 to 2003 who underwent adjuvant RT after surgery. Median follow-up was 43.5 months (range 0.2-173 months). None of these patients were treated with postoperative concomitant chemotherapy. Tumor samples were obtained from surgical specimens. Membrane features (intensity, extension) of EGFR expression were evaluated, and a statistical analysis (univariate and multivariate) was conducted to correlate these parameters with over...
Radiation oncology (London, England), 2006
Epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors. Its stimulation by endogenous ligands, EGF or transforming growth factor-alpha (TGF-alpha) results in activation of intracellular tyrosine kinase, therefore, cell cycle progression. High levels of EGFR expression are correlated with poor prognosis and resistance to radiation therapy in a variety of cancers, mostly in squamous-cell carcinoma of the head and neck (SCCHN). Blocking the EGFR by a monoclonal antibody results in inhibition of the stimulation of the receptor, therefore, in inhibition of cell proliferation, enhanced apoptosis, and reduced angiogenesis, invasiveness and metastases. The EGFR is a prime target for new anticancer therapy in SCCHN, and other agents in development include small molecular tyrosine kinase inhibitors and antisense therapies.
Clinical Cancer Research, 2005
Background: Several lines of evidence support the epidermal growth factor receptor (EGFR) as a molecular target for therapy in head and neck squamous cell carcinomas (HNSCC). Determination of tumor EGFR levels by conventional immunohistochemistry has not always predicted antitumor efficacy. Quantitative assays may provide more accurate assessment of the level of EGFR receptor in the tumor, which may thus provide more reliable prognostic and predictive information. We studied the prognostic value of quantitative assessment of EGFR in oropharyngeal squamous cell cancers treated with radiotherapy. Experimental Design:We studied EGFR protein expression on a tissue microarray composed of 95 oropharyngeal cancer cases using an in situ molecular-based method of quantitative assessment of protein expression (AQUA) and correlated those with clinical and pathologic data. Automated, quantitative analysis uses cytokeratin to define pixels as cancer (tumor mask) within the array spot and measures intensity of EGFR expression using a Cy5-conjugated antibody within the mask. A continuous index score is generated, which is directly proportional to the number of molecules per unit area, and cases were defined as high expressing if they were above the median expression level. Results: The mean follow-up time for survivors was 44.9 months, and for the entire cohort was 34.8 months. Patients with high tumor EGFR expression levels had a local recurrence rate of 58% compared with 17% for patients with low EGFR tumor expression (P < 0.01). Similarly, patients with high nuclear EGFR expression had a local recurrence rate of 54% compared with 21% for patients with low EGFR nuclear expression (P < 0.05). Additionally, patients with high tumor and nuclear EGFR levels had inferior disease-free survival compared with low expressors (19% versus 43% and 19% versus 45%, respectively. P < 0.05 for each). In multivariate analysis adjusting for well-characterized prognostic variables, high tumor and nuclear EGFR expression levels retained their prognostic significance. Conclusion: The AQUA system provides a continuous measurement of EGFR on paraffinembedded tissue and was able to reveal the association between EGFR expression and outcome expected from the biological role of EGFR. In the future, EGFR AQUA score may be useful in predicting response to EGFR-targeted therapies. Mortality rates of patients with head and neck squamous cell cancer (HNSCC) have not improved substantially over the past 30 years, despite advances in diagnosis and therapy (1).
International Journal of Medical Research and Review, 2017
Background: Head and Neck squamous cell carcinoma (HNSCC) is the seventh most common cancer in the world with poor overall survival rate which is unchang ed during the last two decades. Aim: Aim of ou r study is to measure the level o f Epidermal Growth Factor Receptor (EGFR) exp ression in HNSCC by immunohistochemistry (IHC) and to correlate EGFR with clinicopathological variables. Settings and Design: Cross sectional study from 1 st October 2012 to 31st of March 2014 was performed. Materials and Methods: After taking d etailed history and a thorough examination, biopsy/ specimen o f HNSCC region were evaluated to con firm the diagnosis o f HNSCC. Paraffin blocks o f such tumors were process ed for EGFR staining. Staining intensity was evaluated by using scale from 1 to 4. Statistical Analysis: Chi-square test was used as appropriate fo r data analysis. Results: In the present study 38/50 (78%) patients were diagnosed as well differentiated, 12/50(24%) were diagnosed as moderately di fferentiated. For EGFR staining, 24/50 (48%) scored as +2, 16/50(32%) as +3, 8/50(16%) as +1 and 2/50(4%) scored as 0. 23/38(60.5%) well differentiat ed SCC cases pres ented as +2, 5/38(13.2%) as +3, 8/38(21.1%) as +1 and 2/38(5.3%) as 0. 11/12(91.6%) moderately differentiated SCC cas es were sco red as +3, 1/12(8.3%) as +2. p v alue 0.001, which is highly signifi cant. However, correlation o f EGFR scoring with patients age, sex, addiction history, site of the tumor was insignificant. Conclusion: EGFR was highly expressed in HNSCC. The result of our study showed that, high EGFR scoring was associated with high grad e o f the tumor. There was no signi ficant rel ationship between EGFR scoring and clinicopathological variables.
Journal of Oral Pathology & Medicine, 2013
OBJECTIVES: To study immunohistochemical expression of the epithelial growth factor receptor (EGFR) in oral carcinomas and the head and neck region to examine possible associations with various features of the tumors and survival of the patients. MATERIALS AND METHODS: Sections were made from two tissue arrays composed of 206 oral squamous cell carcinomas and 427 squamous cell carcinomas of the head and neck region, respectively, and examined for EGFR expression and Ki-67 labeling index by means of immunohistochemistry, and for EGFR gene amplification by means of fluorescence in situ hybridization. Correlation between resulting parameters and with clinical features was evaluated using chi-square test and Kaplan-Meyer analysis. RESULTS: A statistically significant association was observed for strong EGFR immunohistochemical (IHC) expression with advanced lymph node involvement (P = 0.02). EGFR immunohistochemical expression did not significantly correlate with patient disease specific (DS) or overall survival (OS). EGFR gene amplification was not correlated with any of the tumor features nor to survival of the patients (DS and OS). DISCUSSION: Epithelial growth factor receptor IHC expression and gene amplification might be suitable to predict locoregional control in oral squamous cell carcinoma patients but an inappropriate predictor for patients survival.